Impact of the EMA/FDA alerts on the use of effective contraceptive method in women of childbearing age undergoing valproic acid treatment in a long-stay psychiatric center

[1]  K. Puteikis,et al.  Valproate utilisation trends among girls and women from 2013 to 2018 , 2019, Seizure.

[2]  B. Wettermark,et al.  Valproic acid utilization among girls and women in Stockholm: Impact of regulatory restrictions , 2018, Epilepsia open.

[3]  M. T. Martínez-Lazcano,et al.  Uso de ácido valproico en unidades de psiquiatría de estancia prolongada , 2015 .

[4]  M. Oto,et al.  Teratogenic risk and contraceptive counselling in psychiatric practice: analysis of anticonvulsant therapy , 2013, BMC Psychiatry.

[5]  R. Oliver,et al.  Contraceptive and sexual health care issues in women with schizophrenia , 2013, Journal of Family Planning and Reproductive Health Care.

[6]  Christopher M. Burkle,et al.  Ten common questions (and their answers) about off-label drug use. , 2012, Mayo Clinic proceedings.

[7]  B. Roehr.  Abbott pays $1.6bn for promoting off label use of valproic acid , 2012, BMJ : British Medical Journal.

[8]  M. Seeman,et al.  Prescribing Contraceptives for Women with Schizophrenia , 2011, Journal of psychiatric practice.

[9]  A K Wagner,et al.  Segmented regression analysis of interrupted time series studies in medication use research , 2002, Journal of clinical pharmacy and therapeutics.

[10]  S. Fabro,et al.  TERATOGENIC POTENTIAL OF VALPROIC ACID , 1980, The Lancet.

[11]  M. T. Martínez-Lazcano,et al.  [Use of valproic acid in long stay units of psychiatry]. , 2015, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.

[12]  L. Miller.  Sexuality, reproduction, and family planning in women with schizophrenia. , 1997, Schizophrenia bulletin.